{
    "case_number": "CAC-UDRP-107687",
    "time_of_filling": "2025-06-30 14:58:41",
    "domain_names": [
        "novartissmeds.com"
    ],
    "case_administrator": "Olga Dvořáková (Case admin)",
    "complainant": [
        " Novartis AG "
    ],
    "complainant_representative": "Abion GmbH",
    "respondent": [
        "louis faraway"
    ],
    "respondent_representative": null,
    "factual_background": "<p>The Complainant is one <span>the biggest global pharmaceutical and healthcare groups. It states that it provides solutions to address the evolving needs of patients worldwide by developing and delivering innovative medical treatments and drugs. <\/span><\/p>\n<p>The Complainant, with headquarters in Switzerland, was created in 1996 through a merger of two other companies Ciba-Geigy and Sandoz. The Novartis group achieved net sales of USD 50.3 billion in 2024 and employs approximately 76.000 full-time equivalent employees.<\/p>\n<p>The Complainant is the owner of numerous domain names comprising the mark NOVARTIS, such as &lt;novartis.com&gt;, created on 16 February 1996.<\/p>\n<p>&nbsp;The disputed domain name &lt;novartissmeds.com&gt; was registered on 14 June 2025.<\/p>",
    "other_legal_proceedings": "<p>The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>",
    "no_response_filed": "<p>The Complainant contends that the requirements of the Policy have been met and that the disputed domain name should be transferred to it.<\/p>\n<p><br \/>No administratively compliant Response has been filed.<\/p>",
    "rights": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the Policy).<\/p>",
    "no_rights_or_legitimate_interests": "<p>The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the Policy).<\/p>",
    "bad_faith": "<p>The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the Policy).<\/p>",
    "procedural_factors": "<p>The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>",
    "decision": "Accepted",
    "panelists": [
        "Tom  Heremans"
    ],
    "date_of_panel_decision": "2025-07-25 00:00:00",
    "informal_english_translation": "<p>The Complainant is the owner of several trademarks, comprising the word NOVARTIS, which are registered for a wide range of products and services and which offer protection in many territories throughout the world. The list of trademarks includes for instance:<\/p>\n<p>- the international trademark NOVARTIS, applied for on 15 February 1996 and registered under No. 427370 for several products and services in relation to the pharmaceutical industry;<\/p>\n<p>- the US trademark NOVARTIS, applied for on 12 September 2013 and registered under No. 4986124 for pharmaceutical preparations;<\/p>\n<p>- the US trademark NOVARTIS, applied for on 25 January 2022 and registered under No. 6990442 for a plethora of pharmaceutical products.<\/p>",
    "decision_domains": {
        "novartissmeds.com": "TRANSFERRED"
    },
    "panelist": null,
    "panellists_text": null
}